MiR-27a as an oncogenic microRNA of hepatitis B virus-related hepatocellular carcinoma

Asian Pacific Journal of Cancer Prevention

Volumn 14, Issue 2, 2013, Pages 885-889

  Wu, Xin Jun ^a   Li, Yan ^a   Liu, Dong ^a   Zhao, Lun De ^a   Bai, Bin ^a   Xue, Ming Hui ^a  

^a The Third Hospital of Xinxiang Medical University   (China)

Author keywords

Hepatocellular carcinoma; MicroRNA; Migration and invasion; Mir 27a; Proliferation

Indexed keywords

MICRORNA; MIRN27 MICRORNA, HUMAN;

APOPTOSIS; ARTICLE; CELL CYCLE; CELL MOTION; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION; GENETICS; HEPATITIS B VIRUS; HEPG2 CELL LINE; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; MALE; MIDDLE AGED; TUMOR CELL LINE; TUMOR INVASION; UPREGULATION; VIROLOGY;

APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL CYCLE; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MICRORNAS; MIDDLE AGED; NEOPLASM INVASIVENESS; UP-REGULATION;

EID: 84877678594     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2013.14.2.885     Document Type: Article

References (32)

1. Bartel DP (2004). MicroRNAs: genomics, biogenesis, mechanism, and function. Cell, 116, 281-97.
2. Brase JC, Johannes M, Schlomm T, et al, (2011). Circulating miRNAs are correlated with tumor progression in prostate cancer. Int J Cancer, 128, 608-16.
3. Budhu A, Jia HL, Forgues M, et al, (2008). Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology, 47, 897-907.
4. Chen X, Ba Y, Ma L, et al, (2008). Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res, 18, 997-1006.
5. Chintharlapalli S, Papineni S, Abdelrahim M, et al, (2009). Oncogenic microRNA-27a is a target for anticancer agent methyl2-cyano-3,11-dioxo-18beta-olean-1,12-dien-30-oate in colon cancer cells. Int J Cancer, 125, 1965-74.
6. El-Serag HB, Marrero JA, Rudolph L, Reddy KR (2008). Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology, 134, 1752-63.
7. Garzon R, Calin GA, Croce CM (2009). MicroRNAs in Cancer. Annu Rev Med, 60, 167-79.
8. Gottardo F, Liu CG, Ferracin M, et al, (2007). Micro-RNA profiling in kidney and bladder cancers. Urol Oncol, 25, 387-92.
9. Guttilla IK, White BA (2009). Coordinate regulation of FOXO1 by miR-27a, miR-96, and miR-182 in breast cancer cells. J Biol Chem, 284, 23204-16.
10. Huang Z, Huang D, Ni S, et al, (2010). Plasma microRNAs are promising novel biomarkers for early detection of colorectal cancer. Int J Cancer, 127, 118-26.
11. Jemal A, Bray F, Center MM, et al, (2011). Global cancer statistics. CA Cancer J Clin, 61, 69-90.
12. Ji J, Shi J, Budhu A, et al, (2009). MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med, 361, 1437-47.
13. Jiang J, Gusev Y, Aderca I, et al, (2008). Association of MicroRNA expression in hepatocellular carcinomas with hepatitis infection, cirrhosis, and patient survival. Clin Cancer Res, 14, 419-27.
14. Kasinski AL, Slack FJ (2011). MicroRNAs en route to the clinic: progress in validating and targeting microRNAs for cancer therapy. Nature Reviews Cancer, 11, 849-64.
15. Kutay H, Bai S, Datta J, et al, (2006). Downregulation of miR-122 in the rodent and human hepatocellular carcinomas. J Cell Biochem, 99, 671-8.
16. Ladeiro Y, Couchy G, Balabaud C, et al, (2008). MicroRNA profiling in hepatocellular tumors is associated with clinical features and oncogene/tumor suppressor gene mutations. Hepatology, 47, 1955-63.
17. Lerner M, Lundgren J, Akhoondi S, et al, (2011). MiRNA-27a controls FBW7/hCDC4-dependent cyclin E degradation and cell cycle progression. Cell Cycle, 10, 2172-83.
18. Li LM, Hu ZB, Zhou ZX, et al, (2010). Serum microRNA profiles serve as novel biomarkers for HBV infection and diagnosis of HBV-positive hepatocarcinoma. Cancer Res, 70, 9798-807.
19. Liu H, Zhu L, Liu B, et al, (2012). Genome-wide microRNA profiles identify miR-378 as a serum biomarker for early detection of gastric cancer. Cancer Lett, 316, 196-203.
20. Liu T, Tang H, Lang Y, Liu M, Li X (2009). MicroRNA-27a functions as an oncogene in gastric adenocarcinoma by targeting prohibitin. Cancer Lett, 273, 233-42.
21. Li W, Xie L, He X, et al, (2008). Diagnostic and prognostic implications of microRNAs in human hepatocellular carcinoma. Int J Cancer, 123, 1616-22.
22. Li Z, Hu S, Wang J, et al, (2010). MiR-27a modulates MDR1/P-glycoprotein expression by targeting HIPK2 in human ovarian cancer cells. Gynecol Oncol, 119, 125-30.
23. Ma Y, Yu S, Zhao W, Lu Z, Chen J (2010). miR-27a regulates the growth, colony formation and migration of pancreatic cancer cells by targeting Sprouty2. Cancer Lett, 298, 150-8.
24. McDonald JS, Milosevic D, Reddi HV, Grebe SK, Algeciras-Schimnich A (2011). Analysis of circulating microRNA: preanalytical and analytical challenges. Clin Chem, 57, 833-40.
25. Mertens-Talcott SU, Chintharlapalli S, Li X, Safe S (2007). The oncogenic microRNA-27a targets genes that regulate specificity protein transcription factors and the G2-M checkpoint in MDA-MB-231 breast cancer cells. Cancer Res, 67, 11001-11.
26. Mitchell PS, Parkin RK, Kroh EM, et al,(2008). Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A, 105, 10513-8.
27. Schrauder MG, Strick R, Schulz-Wendtland R, et al,(2012). Circulating micro-RNAs as potential blood-based markers for early stage breast cancer detection. PLoS One, 7, e29770.
28. Szafranska AE, Davison TS, John J, et al,(2007). MicroRNA expression alterations are linked to tumorigenesis and non-neoplastic processes in pancreatic ductal adenocarcinoma. Oncogene, 26, 4442-52.
29. Tinkle CL, Haas-Kogan D (2012). Hepatocellular carcinoma: natural history, current management, and emerging tools. Biologics, 6, 207-19.
30. Zheng D, Haddadin S, Wang Y, et al,(2011). Plasma microRNAs as novel biomarkers for early detection of lung cancer. Int J Clin Exp Pathol, 4, 575-86.
31. Zhou J, Yu L, Gao X, et al,(2011). Plasma microRNA panel to diagnose hepatitis B virus-related hepatocellular carcinoma. J Clin Oncol, 29, 4781-8.
32. Zinkin NT, Grall F, Bhaskar K, et al,(2008). Serum proteomics and biomarkers in hepatocellular carcinoma and chronic liver disease. Clin Cancer Res, 14, 470-7.